Cabaletta Bio
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cabaletta Bio and other ETFs, options, and stocks.About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies.
CEOSteven Nichtberger
CEOSteven Nichtberger
Employees161
Employees161
HeadquartersPhiladelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded2017
Founded2017
Employees161
Employees161
CABA Key Statistics
Market cap254.73M
Market cap254.73M
Price-Earnings ratio-0.91
Price-Earnings ratio-0.91
Dividend yield—
Dividend yield—
Average volume3.44M
Average volume3.44M
High today$2.86
High today$2.86
Low today$2.49
Low today$2.49
Open price$2.56
Open price$2.56
Volume4.27M
Volume4.27M
52 Week high$5.46
52 Week high$5.46
52 Week low$0.9857
52 Week low$0.9857
CABA News
TipRanks 2h
Cabaletta Bio’s RESET-MS Study: A New Frontier in Multiple Sclerosis TreatmentCabaletta Bio, Inc. ((CABA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% o...
TipRanks 9h
Cabaletta Bio Announces Positive Clinical Data UpdatesElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 9h
Cabaletta Bio presents data, development updates for Rese-celCabaletta Bio (CABA) announced positive clinical data and development updates across the RESET-Myositis, RESET-SSc and RESET-SLE trials evaluating rese-cel. The...
Analyst ratings
80%
of 10 ratingsBuy
80%
Hold
20%
Sell
0%
People also own
Based on the portfolios of people who own CABA. This list is generated using Robinhood data, and it’s not a recommendation.